Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system

T. M. Owaidah, A. Al Beihany, M. A. Iqbal, Naser Elkum, G. T. Roberts

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Biphenotypic acute leukemia (BAL) is a rare, difficult to diagnose entity. Its identification is important for risk stratification in acute leukemia (AL). The scoring proposal of the European Group for the Classification of Acute Leukemia (EGIL) is useful for this purpose, but its performance against objective benchmarks is unclear. Using the EGIL system, we identified 23 (3.4%) BAL from among 676 newly diagnosed AL patients. Mixed, small and large blast cells predominated, with FAB M2 and L1 constituting the majority. All patients were positive for myeloid (M) markers and either B cell (B) (17 or 74%) or T cell (T) (8 or 34%) markers with two exceptional patients demonstrating trilineage phenotype. Six (50%) of studied M-B cases were positive for both IGH and TCR. In six (26%) patients myeloid lineage commitment was also demonstrable by electron cytochemistry. Abnormal findings were present in 19 (83%) patients by cytogenetics/FISH/molecular analysis as follows: t(9;22) (17%); MLL gene rearrangement (26%); deletion(6q) (13%); 12p11.2 (9%); numerical abnormalities (13%), and three (13%) new, previously unreported translocations t(X;6)(p22.3;q21); t(2;6)(q37;p21.3); and t(8;14)(p21;q32). In conclusion, the EGIL criteria for BAL appear robust when compared against molecular techniques that, if applied routinely, could aid in detecting BAL and help in risk stratification.

Original languageEnglish
Pages (from-to)620-626
Number of pages7
JournalLeukemia
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2006
Externally publishedYes

Fingerprint

Biphenotypic Acute Leukemia
Cytogenetics
Leukemia
Benchmarking
Histocytochemistry
Gene Rearrangement
B-Lymphocytes
Electrons
T-Lymphocytes
Phenotype

Keywords

  • Biphenotypic
  • Cytogenetic
  • Immunophenotyping
  • Leukemia
  • Molecular

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. / Owaidah, T. M.; Al Beihany, A.; Iqbal, M. A.; Elkum, Naser; Roberts, G. T.

In: Leukemia, Vol. 20, No. 4, 04.2006, p. 620-626.

Research output: Contribution to journalArticle

Owaidah, T. M. ; Al Beihany, A. ; Iqbal, M. A. ; Elkum, Naser ; Roberts, G. T. / Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. In: Leukemia. 2006 ; Vol. 20, No. 4. pp. 620-626.
@article{018e6b003a404f2aacb47eab2d6b0a7e,
title = "Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system",
abstract = "Biphenotypic acute leukemia (BAL) is a rare, difficult to diagnose entity. Its identification is important for risk stratification in acute leukemia (AL). The scoring proposal of the European Group for the Classification of Acute Leukemia (EGIL) is useful for this purpose, but its performance against objective benchmarks is unclear. Using the EGIL system, we identified 23 (3.4{\%}) BAL from among 676 newly diagnosed AL patients. Mixed, small and large blast cells predominated, with FAB M2 and L1 constituting the majority. All patients were positive for myeloid (M) markers and either B cell (B) (17 or 74{\%}) or T cell (T) (8 or 34{\%}) markers with two exceptional patients demonstrating trilineage phenotype. Six (50{\%}) of studied M-B cases were positive for both IGH and TCR. In six (26{\%}) patients myeloid lineage commitment was also demonstrable by electron cytochemistry. Abnormal findings were present in 19 (83{\%}) patients by cytogenetics/FISH/molecular analysis as follows: t(9;22) (17{\%}); MLL gene rearrangement (26{\%}); deletion(6q) (13{\%}); 12p11.2 (9{\%}); numerical abnormalities (13{\%}), and three (13{\%}) new, previously unreported translocations t(X;6)(p22.3;q21); t(2;6)(q37;p21.3); and t(8;14)(p21;q32). In conclusion, the EGIL criteria for BAL appear robust when compared against molecular techniques that, if applied routinely, could aid in detecting BAL and help in risk stratification.",
keywords = "Biphenotypic, Cytogenetic, Immunophenotyping, Leukemia, Molecular",
author = "Owaidah, {T. M.} and {Al Beihany}, A. and Iqbal, {M. A.} and Naser Elkum and Roberts, {G. T.}",
year = "2006",
month = "4",
doi = "10.1038/sj.leu.2404128",
language = "English",
volume = "20",
pages = "620--626",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system

AU - Owaidah, T. M.

AU - Al Beihany, A.

AU - Iqbal, M. A.

AU - Elkum, Naser

AU - Roberts, G. T.

PY - 2006/4

Y1 - 2006/4

N2 - Biphenotypic acute leukemia (BAL) is a rare, difficult to diagnose entity. Its identification is important for risk stratification in acute leukemia (AL). The scoring proposal of the European Group for the Classification of Acute Leukemia (EGIL) is useful for this purpose, but its performance against objective benchmarks is unclear. Using the EGIL system, we identified 23 (3.4%) BAL from among 676 newly diagnosed AL patients. Mixed, small and large blast cells predominated, with FAB M2 and L1 constituting the majority. All patients were positive for myeloid (M) markers and either B cell (B) (17 or 74%) or T cell (T) (8 or 34%) markers with two exceptional patients demonstrating trilineage phenotype. Six (50%) of studied M-B cases were positive for both IGH and TCR. In six (26%) patients myeloid lineage commitment was also demonstrable by electron cytochemistry. Abnormal findings were present in 19 (83%) patients by cytogenetics/FISH/molecular analysis as follows: t(9;22) (17%); MLL gene rearrangement (26%); deletion(6q) (13%); 12p11.2 (9%); numerical abnormalities (13%), and three (13%) new, previously unreported translocations t(X;6)(p22.3;q21); t(2;6)(q37;p21.3); and t(8;14)(p21;q32). In conclusion, the EGIL criteria for BAL appear robust when compared against molecular techniques that, if applied routinely, could aid in detecting BAL and help in risk stratification.

AB - Biphenotypic acute leukemia (BAL) is a rare, difficult to diagnose entity. Its identification is important for risk stratification in acute leukemia (AL). The scoring proposal of the European Group for the Classification of Acute Leukemia (EGIL) is useful for this purpose, but its performance against objective benchmarks is unclear. Using the EGIL system, we identified 23 (3.4%) BAL from among 676 newly diagnosed AL patients. Mixed, small and large blast cells predominated, with FAB M2 and L1 constituting the majority. All patients were positive for myeloid (M) markers and either B cell (B) (17 or 74%) or T cell (T) (8 or 34%) markers with two exceptional patients demonstrating trilineage phenotype. Six (50%) of studied M-B cases were positive for both IGH and TCR. In six (26%) patients myeloid lineage commitment was also demonstrable by electron cytochemistry. Abnormal findings were present in 19 (83%) patients by cytogenetics/FISH/molecular analysis as follows: t(9;22) (17%); MLL gene rearrangement (26%); deletion(6q) (13%); 12p11.2 (9%); numerical abnormalities (13%), and three (13%) new, previously unreported translocations t(X;6)(p22.3;q21); t(2;6)(q37;p21.3); and t(8;14)(p21;q32). In conclusion, the EGIL criteria for BAL appear robust when compared against molecular techniques that, if applied routinely, could aid in detecting BAL and help in risk stratification.

KW - Biphenotypic

KW - Cytogenetic

KW - Immunophenotyping

KW - Leukemia

KW - Molecular

UR - http://www.scopus.com/inward/record.url?scp=33646477994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646477994&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404128

DO - 10.1038/sj.leu.2404128

M3 - Article

VL - 20

SP - 620

EP - 626

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -